Fortrea Holdings Inc. (FTRE)
(Delayed Data from NSDQ)
$19.26 USD
+0.76 (4.11%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $19.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.26 USD
+0.76 (4.11%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $19.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Fortrea Holdings Inc. (FTRE) Lags Q3 Earnings Estimates
by Zacks Equity Research
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -14.81% and 0.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 28.57% and 12.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 53.85% and 0.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 8.25% and 1.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Fortrea Holdings (FTRE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Fortrea Holdings (FTRE) stock based on the movements in the options market lately.
Fortrea Holdings Inc. (FTRE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -142.86% and 3.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
InflaRx (IFRX) delivered earnings and revenue surprises of -23.81% and 83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Caribou Biosciences (CRBU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Fortrea Holdings Inc. (FTRE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Group (ENSG) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 2.33% and 1.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Fortrea (FTRE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Fortrea (FTRE) stock based on the movements in the options market lately.
Company News for Mar 12, 2024
by Zacks Equity Research
Companies in The News Are: LEGN, BA, ALK, FTRE, AVGO.
Cognizant (CTSH), Microsoft Team Up to Streamline Healthcare
by Zacks Equity Research
Cognizant (CTSH) and Microsoft join forces to transform healthcare admin with generative AI integration on TriZetto.
Cognizant (CTSH) Expands Gen-AI Footprint With Flowsource
by Zacks Equity Research
Cognizant (CTSH) launches Flowsource, which expands its footprint in the growing generative AI footprint.
Cognizant (CTSH) Boosts Innovation With Microsoft AI Assistant
by Zacks Equity Research
Cognizant (CTSH) and Microsoft's Innovation Assistant, powered by Azure OpenAI, boosts creative problem-solving in client challenges through Bluebolt.
Cognizant (CTSH) Expands Healthcare Footprint With Fortrea Deal
by Zacks Equity Research
Cognizant (CTSH) drives Fortrea's digital journey, reshaping the CRO industry with a four-year transformative technology partnership.
Stock Market News for Nov 14, 2023
by Zacks Equity Research
Wall Street closed mixed on Monday as market participants awaited the release of a key inflation data.
Zacks.com featured highlights include Intrepid Potash, Fortrea Holdings and Cricut
by Zacks Equity Research
Intrepid Potash, Fortrea Holdings and Cricut are part of the Zacks Screen of the Week article.
New Analysts Initiate Coverage: 3 Stocks to Watch
by Shrabana Mukherjee
The recent surge in analyst coverage for stocks such as Intrepid Potash (IPI), Fortrea (FTRE) and Cricut (CRCT) indicates the potential for significant price appreciation in the near term.